Suchergebnisse - "Herrington, William G"

PubPharm (5)

1

UK Kidney Association Clinical Practice Guideline : Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE

enthalten in: BMC nephrology | 2023

von Roddick, A. | Wonnacott, A. | Webb, D. | +15

2

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria : clinical implications when using SGLT-2 inhibitors

enthalten in: Kidney international | 2023

von Chapman, D. | Judge, P. | Sardell, R. | +11

CommentIn: Kidney Int. 2023 Jul;104(1):201. - PMID 37349050

3

In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes

enthalten in: Annals of internal medicine | 2020

von Ai Ng, S. | Zhu, D. | Herrington, W.

CommentOn: Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. - PMID 31495651

4

In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function

enthalten in: Annals of internal medicine | 2019

von Herrington, W. | Zhu, D. | Haynes, R.

CommentOn: Circulation. 2018 Oct 9;138(15):1537-1550. - PMID 29941478

5

Metformin : the safest hypoglycaemic agent in chronic kidney disease?

enthalten in: Nephron. Clinical practice | 2011

von Nye, H. | Herrington, W.

1
[1]